Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

Jun Guo*, Yiran Huang, Xu Zhang, Fangjian Zhou, Yinghao Sun, Shukui Qin, Zhangqun Ye, Hui Wang, Annette Jappe, Patrick Straub, Nicoletta Pirotta and Sven Gogov

BMC Cancer 2013, 13:136  doi:10.1186/1471-2407-13-136

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Post a comment